Federal biotech office gets power to override agency disagreements on product safety

What it does

This bill establishes a National Biotechnology Initiative—a coordinated federal effort across 13+ agencies (Defense, Commerce, Health, Energy, NSF, etc.) to advance biotechnology research, commercialization, and workforce development. It creates a new National Biotechnology Coordination Office in the Executive Office of the President, appoints a Director, and mandates interagency planning, regulatory streamlining, biosafety oversight, and public communication about biotech. The bill funds the office at $22–35M annually through 2030 and requires a national biotech strategy within 2 years.

Why we flagged it

The bill's core function is to establish federal coordination infrastructure for biotechnology R&D and commercialization, with explicit emphasis on 'regulatory streamlining' and 'private sector translation.' While framed as national security and competitiveness, the mechanism prioritizes industry acceleration alongside public research.

What the text implies

• The 'regulatory streamlining' provisions (Section 6, subsection on regulatory streamlining) authorize the OMB Director to override interagency disagreement and impose clear regulatory pathways unilaterally. This may bypass traditional agency review and public comment for novel biotech products.
• The bill exempts the Director's expert-convening activities from the Federal Advisory Committee Act (Section 5), allowing closed-door biotech policy advice without public transparency or conflict-of-interest disclosures.
• Biological data is designated a 'strategic national resource' and the bill mandates centralized databases with 'appropriate protections'—but does not define those protections, leaving privacy and security standards to future rulemaking.
• The 20-year wind-down clause (Section 4) transitions the Office to an 'executive secretariat' role, potentially embedding biotech coordination permanently in the Executive Office without future congressional reauthorization.
• Private-sector 'testbeds' and 'user facilities' for biotech scale-up are funded and coordinated federally, effectively subsidizing industry infrastructure development under the guise of research support.

Who it affects

The bill creates public benefits (workforce training, biosafety oversight, public education, research coordination) and potential efficiency gains through regulatory streamlining. However, it also prioritizes private-sector commercialization and regulatory easing for biotech products with minimal transparency guardrails, and the 'regulatory streamlining' language may weaken safety review for novel organisms or products. The balance between public health protection and industry acceleration is un

Who stands to gain

• biotechnology companies (especially those in biomanufacturing, synthetic biology, and genomics)
• pharmaceutical and life sciences firms (Biogen, Pfizer, others mapped)
• defense contractors with biotech divisions
• small biotech startups (via SBIR/STTR programs)
• academic research institutions (NIH, NSF funding flows)
• industrial biotech and biomanufacturing facilities

Named in the bill

National Biotechnology Coordination Office, National Biotechnology Initiative, Interagency Committee, Director of National Biotechnology Coordination Office, Department of Defense, Department of Commerce, Department of Health and Human Services, National Science Foundation, Office of Management and Budget, Small Business Innovation Research Program, Small Business Technology Transfer Program, Comptroller General — and 2 more

Where it stands

23 cosponsors: 15 Democrats, 8 Republicans.

• Apr 9, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 9, 2025 — Referred to House Committee on Education and Workforce and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Science, Space, and Technology, and in addition to the Committees on Foreign…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,090,000 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Stephanie Bice, the sponsor, reported $1,071,750 in PAC receipts in the 2026 cycle.

• Archer Daniels Midland Company — $1,500,000 on 1 filing
• Novozymes North America, Inc. — $290,000 on 2 filings
• With Honor Action, Inc. — $140,000 on 1 filing
• American Society for Microbiology — $100,000 on 2 filings
• American Alliance for Biomanufacturing — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.